Bapotulimab  (Synonyms: BAY-1905254)

Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects^[1].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

Bapotulimab blocks the immunosuppressive effects of ILDR2 on T-cell activation. Bapotulimab is mouse/human cross-reactive, as ILDR2 has a 98% sequence identity between the extracellular domains of human and murine orthologs^[1].
Bapotulimab (BAY-1905254; 5, 25, 100, or 500 ng/mL) promotes T-cell activation in vitro and enhance antigen-specific T-cell proliferation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bapotulimab (BAY-1905254; 10 mg/kg; i.p.; on days 1 and 4) shows significantly increased antigen-specific T-cell proliferation and cytotoxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2359413-58-2

Liquid

Colorless to light yellow

[Bapotulimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• [1]. Julia Huetter, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911.  [Content Brief]